Petros Grivas, MD, PhD, discusses posthoc findings from the phase 3 JAVELIN Bladder 100 trial presented during the 2021 ASCO Annual Meeting. Based on the primary findings from the trial, the FDA previously approved avelumab (Bavencio) as a frontline maintenance therapy in patients with advanced urothelial cancer that has not progressed with first-line platinum-based chemotherapy.
Grivas is global co-principal investigator on the JAVELIN Bladder 100 trial and associate professor and clinical director of the Genitourinary Cancers Program at Seattle Cancer Care Alliance, and associate professor, Division of Medical Oncology, University of Washington School of Medicine.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.